Evaluation of Carbohydrates Part 2

NCT ID: NCT03293706

Last Updated: 2017-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-21

Study Completion Date

2017-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is single-blind with a randomized, cross-over design to evaluate gastrointestinal tolerance of carbohydrate blends.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastro-Intestinal Tolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CHO Control 1 Glucose

25 g glucose

Group Type ACTIVE_COMPARATOR

CHO Control 1 and 2 Glucose

Intervention Type OTHER

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

CHO Control 2 Glucose

25 g glucose

Group Type ACTIVE_COMPARATOR

CHO Control 1 and 2 Glucose

Intervention Type OTHER

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

CHO Experimental 1 Slowly Digested

25 g slowly-digested carbohydrate blend

Group Type EXPERIMENTAL

CHO Experimental 1 Slowly Digested

Intervention Type OTHER

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

CHO Experimental 2 Digestion Resistant

25 g digestion-resistant carbohydrate blend

Group Type EXPERIMENTAL

CHO Experimental 2 Digestion Resistant

Intervention Type OTHER

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

CHO Experimental 3 Low Sugar

25 g low sugar carbohydrate blend

Group Type EXPERIMENTAL

CHO Experimental 3 Low Sugar

Intervention Type OTHER

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

CHO Experimental 4 Maltodextrin

25 g maltodextrin

Group Type EXPERIMENTAL

CHO Experimental 4 Maltodextrin

Intervention Type OTHER

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CHO Control 1 and 2 Glucose

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention Type OTHER

CHO Experimental 1 Slowly Digested

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention Type OTHER

CHO Experimental 2 Digestion Resistant

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention Type OTHER

CHO Experimental 3 Low Sugar

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention Type OTHER

CHO Experimental 4 Maltodextrin

mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or non-pregnant females in good health.
* Eligible to receive income in Canada and must demonstrate OHIP or equivalent medical coverage.

Exclusion Criteria

* Subject with any type of food allergy or with a known history of AIDS, hepatitis, diabetes, cardio-vascular disease or GI disease.
* Subject taking medication, or with any condition which might, in the opinion of the PI either make participation dangerous to the subject or to others or affect the results.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Nutrition

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vikkie Mustad, PhD

Role: STUDY_CHAIR

Abbott Nutrition

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Glycemic Index Laboratories, Inc.

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BL37 Part 2

Identifier Type: -

Identifier Source: org_study_id